Guangzhou Darui Biotechnology Co., Ltd. 2025 Semi-Annual Performance Forecast [Current Period Performance Forecast](index=1&type=section&id=I.%20Current%20Period%20Performance%20Forecast) The company anticipates a narrower net loss attributable to shareholders for H1 2025, ranging from 140 million to 200 million yuan, though non-recurring adjusted net loss is expected to widen 2025 Semi-Annual Performance Forecast | Item | Current Period | Prior Year Period | | :--- | :--- | :--- | | **Net Profit Attributable to Shareholders of Listed Company** | Loss: 140.00 million – 200.00 million yuan | Loss: 399.22 million yuan | | **Net Profit After Deducting Non-Recurring Gains and Losses** | Loss: 220.00 million – 310.00 million yuan | Loss: 178.75 million yuan | | **Basic Earnings Per Share** | Loss: 0.10 – 0.14 yuan/share | Loss: 0.28 yuan/share | [Communication with Accounting Firm](index=1&type=section&id=II.%20Communication%20with%20Accounting%20Firm) The company explicitly states that this performance forecast has not been pre-audited by an accounting firm - This performance forecast has not been pre-audited by an accounting firm[4](index=4&type=chunk) [Explanation of Performance Changes](index=1&type=section&id=III.%20Explanation%20of%20Performance%20Changes) The overall net loss narrowed due to non-recurring gains from fair value increases in other non-current financial assets, while core business loss widened due to reduced revenue, increased credit impairment, and higher intangible asset amortization [Reasons for Changes in Net Profit Attributable to Parent](index=1&type=section&id=(I)%20Primary%20Reasons%20for%20Changes%20in%20the%20Company's%202025%20Semi-Annual%20Net%20Profit%20Attributable%20to%20Shareholders%20of%20Listed%20Company) Net profit attributable to shareholders improved (loss narrowed) primarily due to an increase in the fair value of other non-current financial assets, recognized as non-recurring income - Net profit attributable to the parent increased compared to the prior year, primarily due to non-recurring gains from the fair value increase of other non-current financial assets[5](index=5&type=chunk) [Reasons for Changes in Non-Recurring Adjusted Net Profit](index=1&type=section&id=(II)%20Primary%20Reasons%20for%20Changes%20in%20the%20Company's%202025%20Semi-Annual%20Net%20Profit%20After%20Deducting%20Non-Recurring%20Gains%20and%20Losses) Non-recurring adjusted net profit declined (loss widened) due to reduced operating revenue from industry demand shifts and centralized procurement, increased credit impairment losses, and higher amortization of self-developed intangible assets - Non-recurring adjusted net profit decreased (loss widened) due to three main reasons: - Operating revenue decreased due to changes in industry demand and centralized procurement price adjustments[5](index=5&type=chunk) - Increased provision for credit impairment losses[6](index=6&type=chunk) - Increased amortization of self-developed intangible assets (registration certificates)[6](index=6&type=chunk) [Other Relevant Information](index=2&type=section&id=IV.%20Other%20Relevant%20Information) The company emphasizes that this performance forecast is a preliminary, unaudited result from the finance department, with final accurate data to be disclosed in the 2025 semi-annual report, urging investor caution - This performance forecast is a preliminary, unaudited result from the company's finance department, with specific financial data subject to the 2025 semi-annual report[7](index=7&type=chunk)

证券代码：002030 证券简称：达安基因 公告编号：2025-038 广州达安基因股份有限公司 广州达安基因股份有限公司（以下简称"公司"）及公司全资子公司广州市 达安基因科技有限公司（以下简称"达安科技"）近日分别收到参股公司杭州安 杰思医学科技股份有限公司（以下简称"安杰思"）的现金分红款，具体情况如 下： 根据安杰思 2024 年年度股东大会会议决议，其利润分配方案为：安杰思 2024 年度拟以实施权益分派股权登记日登记的总股本（扣减回购专用证券账户的股份） 为基数分配利润，每 10 股派发现金红利 13.7350 元（含税），共计派发现金红 利 111,196,251.15 元（含税，保留小数点后两位）。公司持有安杰思股份 8,400,000 股，本次分红金额为 11,537,400 元。公司全资子公司达安科技持有安杰思股份 3,625,495 股，本次分红金额为 4,979,617.38 元。 近日，本公司已收到上述分红款 11,537,400 元，本公司全资子公司达安科技 已收到上述分红款 4,979,617.38 元。上述利润分配将增加本公司 2025 年度合并 报表净利润 16,517,01 ...

证券代码：002030 证券简称：达安基因 公告编号：2025-037 广州达安基因股份有限公司 关于下属子公司取得一个医疗器械注册证的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，本公司下属控股子公司广州市达瑞生物技术股份有限公司取得国家药 品监督管理局颁发的医疗器械注册证一个，具体为： 2025 年 6 月 24 日 医疗器械名称:人类免疫缺陷病毒抗原抗体对照品，注册证编号：国械注准 20253401178。有效期自批准之日起至 2030 年 6 月 19 日。预期用途：本产品与 广州市达瑞生物技术股份有限公司的人类免疫缺陷病毒抗原抗体检测试剂盒（化 学发光免疫分析法）配套使用，用于人类免疫缺陷病毒抗原抗体定性项目的临界 值的确定。 目前，公司控股子公司广州市达瑞生物技术股份有限公司已获得"人类免疫 缺陷病毒抗原抗体对照品"的医疗器械注册证，上述产品尚处于市场开发阶段， 市场需求存在不确定性，敬请投资者注意风险。 特此公告。 广州达安基因股份有限公司 董 事 会 ...

Core Viewpoint - The third-party medical testing industry in China has experienced significant growth, particularly during the pandemic, with a market size reaching 630.5 billion yuan in 2022, but is expected to return to pre-pandemic levels in 2023 and stabilize around 388.8 billion yuan in 2024 [1][6]. Group 1: Industry Definition and Business Model - Medical testing is a discipline that utilizes modern physical and chemical methods for clinical diagnosis and treatment [2]. - Independent clinical laboratories (ICLs), also known as third-party medical laboratories, operate independently of hospitals and are licensed by health authorities to provide clinical testing and pathology services [2]. Group 2: Current Development Status - The ICL industry in China began in the 1980s and has become an essential part of the healthcare system due to increasing demand and favorable policies [4]. - The number of ICLs has grown from fewer than 70 in 2009 to an estimated 2,800 by 2024, with projections of reaching 2,845 by 2025 [4]. Group 3: Market Size and Growth Projections - The market size for third-party medical testing services in China was 630.5 billion yuan in 2022, with a significant drop expected in 2023 as pandemic testing demands decrease [6]. - The projected market size for 2024 is 388.8 billion yuan, with special testing accounting for 189.3 billion yuan and general testing for 199.5 billion yuan [6]. - By 2025, the market is expected to grow to approximately 444.9 billion yuan, with special testing at 218.1 billion yuan and general testing at 226.8 billion yuan [6]. Group 4: Industry Chain Structure - The third-party medical testing industry relies on specialized medical services, acting as a substitute for traditional hospital testing departments [8]. - The upstream of the industry includes suppliers of medical devices and testing reagents, while the downstream consists of various healthcare institutions that increasingly outsource testing services [8]. Group 5: Competitive Landscape - The market is characterized by a concentration of major players, with KingMed and Dian Diagnostics holding a combined market share of 36.16% [15]. - KingMed leads the market with a 17.04% share, providing services to over 20,000 medical institutions across 31 provinces and regions [15]. - Smaller third-party testing institutions face challenges due to limited scale and capabilities, leading to market exit pressures since 2015 [15]. Group 6: Financial Performance of Key Players - In 2024, KingMed reported revenues of 6.627 billion yuan, Dian Diagnostics 4.520 billion yuan, and Aidi Kang 2.914 billion yuan, among others [18]. Group 7: Development Trends - The third-party medical testing sector is becoming increasingly important, with regulatory changes posing new challenges [20]. - The industry is expected to focus on technological upgrades and strategic partnerships to enhance profitability and service quality [20]. - Automation, platformization, and intelligence are emerging as key trends in the development of third-party medical laboratories [20].

Group 1 - The company held its second temporary board meeting of 2025 on June 18, 2025, with all 9 board members present, and the meeting complied with relevant laws and regulations [1] - The board approved an adjustment to the company's organizational structure to enhance governance, asset management, and operational efficiency, including the establishment of new departments: Strategic Planning, Academic Promotion, and Asset Management, while renaming the Engineering Department to Safety Production and Property Management [2] - The board also approved the appointment of Yuan Yifan as the assistant to the general manager for a term of three years, aligning with the current board's term [2] Group 2 - Yuan Yifan has no shares in the company and has no relationships with other board members or significant shareholders, meeting all legal and regulatory requirements for the position [3] - His qualifications include a bachelor's degree from China Pharmaceutical University and previous roles in various biotechnology companies, indicating relevant experience for his new position [2][3]

广州达安基因股份有限公司（以下简称"达安基因"、"公司"）于 2025 年 6 月 13 日以邮件的形式发出会议通知，于 2025 年 6 月 18 日上午 10：00 在广州市 高新区科学城香山路 19 号公司一楼会议室以现场和通讯表决相结合的方式召开 第九届董事会 2025 年第二次临时会议。本次会议由董事长韦典含女士主持，会 议应到董事 9 名，实到董事 9 名。会议的召开符合《公司法》《公司章程》以及 有关法律、法规的规定。本次会议以投票表决的方式，审议并通过了以下决议： 一、会议以 9 票赞成，0 票反对，0 票弃权的表决结果审议通过了公司《关 于调整公司组织架构的议案》。 为了更好地满足公司战略发展需要，围绕聚焦公司业务领域及经营发展目标， 进一步完善公司治理结构，实现公司资产集中化、精细化管理，提升公司运营质 效、管理水平和业务拓展能力，董事会同意公司对现有的组织架构进行调整。具 体调整如下：新设战略规划部、学术推广部、资产管理部；原工程部更名为安全 生产与物业管理部。 二、会议以 9 票赞成，0 票反对，0 票弃权的表决结果审议通过了公司《关 于聘任公司总经理助理的议案》。 证券代码：0020 ...

Core Points - The case involves Dong Hua, former director of the laboratory department at Gong'an County People's Hospital, who was sentenced to 10 years in prison for accepting bribes totaling 6.5 million yuan from five entities and individuals between 2010 and 2023 [2][12] - The bribes were linked to the procurement of medical equipment, reagents, and consumables at the hospital, with one of the bribers being the regional director of the publicly listed company Da An Gene [2][9] Summary by Sections Case Background - Dong Hua, born in October 1962, served as the laboratory department head and later as a technical leader in multiple departments at Gong'an County People's Hospital, which has over 1,400 employees and an annual outpatient volume of approximately 530,000 [4][5] - The investigation into Dong Hua began in March 2024, leading to his detention in April 2024 [5][6] Charges and Conviction - The prosecution charged Dong Hua with two crimes: bribery and money laundering. The bribery involved receiving 6.5 million yuan from various companies, including Wuhan Zhongtianda Technology Co., Ltd., Wuhan Bozhe Trading Co., Ltd., and Da An Gene's regional director [7][9] - The actual control of Zhongtianda and Bozhe companies is held by Xu Zhiguo, who agreed to pay Dong Hua a 20% kickback on sales to the hospital, totaling 2.87 million yuan [7][8] Involvement of Da An Gene - Da An Gene's regional director, Qiao Peng, was involved in the bribery, giving Dong Hua a total of 20,000 yuan over two years [9] - Da An Gene, a publicly listed company, has seen significant revenue growth from 2019 to 2022, with revenues of 5.341 billion yuan in 2020, 7.664 billion yuan in 2021, and 12.046 billion yuan in 2022 [9] Money Laundering Charges - In addition to bribery, Dong Hua was charged with money laundering for transferring 191,500 yuan into bank accounts under the name of his former housekeeper, Guo Zhixiang, between March 2021 and October 2022 [11] - Guo Zhixiang was later implicated in a theft case related to the funds stored in her accounts [11] Sentencing - The court sentenced Dong Hua to 10 years in prison for bribery and 6 months for money laundering, with a total fine of 1 million yuan [12]

证券代码：002030 证券简称：达安基因 公告编号：2025-035 截至目前，公司全资子公司广州市达安基因科技有限公司持有雅莎股份 9.2095%的股权。根据全国中小企业股份转让系统有限责任公司公告，雅莎股份 具体终止挂牌时间为 2025 年 6 月 10 日，雅莎股份目前正在按照中国证券登记结 算有限责任公司北京分公司相关规定办理后续手续。 雅莎股份在全国中小企业股份转让系统终止挂牌不会影响其正常业务的开 展。该事项不会对我公司的生产经营产生重大影响。 特此公告。 广州达安基因股份有限公司 董 事 会 2025 年 6 月 11 日 广州达安基因股份有限公司 关于参股孙公司获批在全国中小企业股份转让系统 终止挂牌的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，广州达安基因股份有限公司（以下简称"达安基因"、"公司"）参 股孙公司珠海雅莎生物科技股份有限公司(以下简称"雅莎股份")收到全国中 小企业股份转让系统有限责任公司出具的《关于同意珠海雅莎生物科技股份有限 公司股票终止在全国中小企业股份转让系统挂牌的函》（股转函[2025]807 ...

证券代码：002030 证券简称：达安基因 公告编号：2025-034 广州达安基因股份有限公司 关于取得一个医疗器械注册证的提示性公告 董 事 会 2025 年 6 月 9 日 医疗器械名称：六项呼吸道病原体核酸检测试剂盒（PCR-荧光探针法），注 册证编号：国械注准 20253401117。有效期自批准之日起至 2030 年 6 月 5 日。 预期用途：本产品用于定性检测人口咽拭子中 6 项呼吸道病原体核酸，包括呼吸 道合胞病毒、人博卡病毒、腺病毒、鼻病毒、肺炎衣原体和肺炎支原体。 上述医疗器械注册证的取得丰富了公司的产品组合，拓宽了公司产品的应用 领域。目前，上述产品尚处于市场开发阶段，市场需求存在不确定性，请广大投 资者注意投资风险。 特此公告。 广州达安基因股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，广州达安基因股份有限公司（以下简称"公司"）取得国家药品监督 管理局颁发的医疗器械注册证一个，具体为： ...

根据安必平 2024 年年度股东大会决议，其利润分配方案为：以方案实施前 的总股本 93,567,699 股为基数，每股派发现金红利 0.10 元（含税），共计派发 现金红利 9,356,769.90 元。公司全资子公司达安科技对安必平持股比例约为 3.73%，本次现金分红金额为 348,600.00 元。 近日，公司全资子公司达安科技已收到上述现金分红款 348,600.00 元。上 述利润分配将增加本公司 2025 年度合并报表净利润 348,600.00 元。 特此公告。 证券代码：002030 证券简称：达安基因 公告编号：2025-033 广州达安基因股份有限公司 关于全资子公司收到现金分红款的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广州达安基因股份有限公司（以下简称"公司"）全资子公司广州市达安基 因科技有限公司（以下简称"达安科技"）近日收到其参股公司广州安必平医药 科技股份有限公司（以下简称"安必平"）的现金分红款，具体情况如下： 广州达安基因股份有限公司 董 事 会 2025 年 5 月 29 日 ...